

primary studies - published RCT

One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements.

Code: PM19207231

Year: 2009 **Date:** 2012

Author: Mozzillo E

Study design (if review, criteria of inclusion for studies)

prospective, randomized, double-blind, parallel-group, controlled study

Participants

patients with cystic fibrosis and lung disease

Interventions

a hypertonic saline solution containing hyaluronic acid (Hyaneb) versus standard hypertonic saline

Outcome measures

tolerability of hypertonic saline

Main results

The results showed that nebulized Hyaneb was more effective in reducing the need for beta(2) bronchodilators and caused a significant reduction in the incidence of adverse effects compared with nebulized hypertonic saline solution alone. Its safety profile indicates that Hyaneb can be used for the treatment of lung disease in cystic fibrosis.

<http://dx.doi.org/10.1111/j.1399-5448.2008.00451.x>

See also

Pediatr Diabetes. 2009;10:162-7

Keywords

Adolescent; Child; hyaluronic acid; hydration; Hypertonic Solutions; Inhalation OR nebulised; pharmacological_intervention; Airway clearance drugs -expectorants- mucolytic- mucociliary-; Respiratory System Agents;